Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rubitecan vs Best Choice in Refractory Pancreatic Cancer
NCT00005870Phase 3Unknown
- Sponsor
- Astex Pharmaceuticals
- Start
- Mar 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rubitecan in pancreatic adenocarcinoma (PDAC), sponsored by Astex Pharmaceuticals. Status: unknown.
02
Drugs
rubitecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00005870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005870.